Donald Notman - Ocular Therapeutix Chief Officer
| OCUL Stock | USD 7.14 0.20 2.88% |
Executive
Mr. Donald D. Notman Jr. is Chief Financial Officer of the company. Prior to joining Ocular Therapeutix, Mr. Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the Company financial operations, business development activities, and strategic planning functions. Previously, Mr. Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC, where he was involved in the buildout of the firm healthcare investment banking capabilities. Before joining Leerink, Mr. Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown Sons since 2017.
| Age | 57 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 15 Crosby Drive, Bedford, MA, United States, 01730 |
| Phone | 781 357 4000 |
| Web | https://www.ocutx.com |
Latest Insider Transactions
Notman received his M.B.A. from The Tuck School of Business at Dartmouth College and his B.A. in Economics from Middlebury College.Donald Notman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Donald Notman against Ocular Therapeutix stock is an integral part of due diligence when investing in Ocular Therapeutix. Donald Notman insider activity provides valuable insight into whether Ocular Therapeutix is net buyers or sellers over its current business cycle. Note, Ocular Therapeutix insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ocular Therapeutix'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Donald Notman over two weeks ago Acquisition by Donald Notman of 344115 shares of Ocular Therapeutix at 7.44 subject to Rule 16b-3 | ||
Donald Notman over three weeks ago Disposition of 6301 shares by Donald Notman of Ocular Therapeutix at 7.84 subject to Rule 16b-3 | ||
Donald Notman over six months ago Acquisition by Donald Notman of 33602 shares of Ocular Therapeutix at 8.56 subject to Rule 16b-3 |
Ocular Therapeutix Management Efficiency
The company has return on total asset (ROA) of (0.2736) % which means that it has lost $0.2736 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9689) %, meaning that it created substantial loss on money invested by shareholders. Ocular Therapeutix's management efficiency ratios could be used to measure how well Ocular Therapeutix manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.3. The value of Return On Capital Employed is expected to slide to -0.36. At this time, Ocular Therapeutix's Asset Turnover is quite stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Thomas Rollins | Assembly Biosciences | 69 | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Stephen MBA | Inozyme Pharma | 66 | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| JD Esq | Terns Pharmaceuticals | 56 | |
| FASCP MD | Inozyme Pharma | 70 | |
| MS MBA | PDS Biotechnology Corp | 59 | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Chau MBA | CytomX Therapeutics | N/A | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Amy CFA | Assembly Biosciences | N/A | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Mark MBA | X4 Pharmaceuticals | 61 | |
| Richard Colonno | Assembly Biosciences | 74 | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Spencer JD | PDS Biotechnology Corp | 55 | |
Management Performance
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.27 |
Ocular Therapeutix Leadership Team
Elected by the shareholders, the Ocular Therapeutix's board of directors comprises two types of representatives: Ocular Therapeutix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ocular. The board's role is to monitor Ocular Therapeutix's management team and ensure that shareholders' interests are well served. Ocular Therapeutix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ocular Therapeutix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pravin MD, Executive Chairman | ||
| William Slattery, Vice Relations | ||
| Todd Anderman, Chief Secretary | ||
| William II, Vice Marketing | ||
| Peter MD, Chief Officer | ||
| Donald Notman, Chief Officer | ||
| Philip Esq, General Counsel | ||
| Rabia MD, Chief Officer | ||
| Antony Mattessich, President CEO, Director | ||
| Christopher White, Senior Vice President Head of Business and Corporate Development | ||
| Peter Jarrett, Chief Officer | ||
| Tracy Smith, Vice Resources | ||
| Jeffrey MD, Chief Officer | ||
| Philip Strassburger, G Counsel | ||
| Scott Corning, VP Commercial | ||
| Steve Meyers, Senior Commercial | ||
| Todd JD, Chief Secretary | ||
| Barry MS, Chief Officer | ||
| KarenLeigh MBA, Senior Operations | ||
| Sanjay MBBS, Chief Officer |
Ocular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ocular Therapeutix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.84) % | ||||
| Operating Margin | (2.98) % | ||||
| Current Valuation | 770.44 M | ||||
| Shares Outstanding | 157.22 M | ||||
| Shares Owned By Insiders | 1.15 % | ||||
| Shares Owned By Institutions | 86.05 % | ||||
| Number Of Shares Shorted | 11.6 M | ||||
| Price To Earning | (2.69) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share | Quarterly Revenue Growth 0.023 | Return On Assets | Return On Equity |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.